Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.


INTRODUCTION Currently available stem cell mobilizing regimens (G-CSF +/- chemotherapy) show high failure rates, especially in heavily pretreated patients. Plerixafor, a new stem cell mobilizing agent blocking the CXCR4-SDF-1 interaction, offers a new strategy for stem cell mobilization, especially in poor mobilizers.This study reports on the outcome of the… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.